



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/825,423	04/03/2001	Patricia C. Weber	ID01152	2057
24265	7590	07/26/2007	EXAMINER	
SCHERING-PLOUGH CORPORATION			STEADMAN, DAVID J	
PATENT DEPARTMENT (K-6-1, 1990)				
2000 GALLOPING HILL ROAD			ART UNIT	PAPER NUMBER
KENILWORTH, NJ 07033-0530			1656	
			MAIL DATE	DELIVERY MODE
			07/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/825,423	WEBER ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	David J. Steadman	1656

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 18 May 2007.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1,7-9,11,21 and 22 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) 11 is/are allowed.  
 6) Claim(s) 1,7-9,21 and 22 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____

## DETAILED ACTION

### *Status of the Application*

- [1] Claims 1, 7-9, 11, and 21-22 are pending in the application.
- [2] Applicant's amendment to the claims, filed on 5/18/07, is acknowledged. This listing of the claims replaces all prior versions and listings of the claims.
- [3] Applicant's arguments filed on 5/18/07 in response to the Office action mailed on 1/10/07 have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.
- [4] The text of those sections of Title 35, U.S. Code not included in the instant action can be found in a prior Office action.
- [5] The indicated allowability of claims 9 and 21-22 is withdrawn in view of the new rejections set forth below.

### *Claim Rejections - 35 USC § 112, First Paragraph*

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

- [6] Claim(s) 1, 7-9, and 21-22 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time

Art Unit: 1656

the application was filed, had possession of the claimed invention. This is a written description rejection.

According to MPEP 2163.II, the methodology for determining the adequacy of written description involves determining what the claim as a whole covers. See particularly MPEP 2163.II.1, which states, “[c]laim construction is an essential part of the examination process. Each claim must be separately analyzed and given its broadest reasonable interpretation in light of and consistent with the written description. See, e.g., *In re Morris*, 127 F.3d 1048, 1053-54, 44 USPQ2d 1023, 1027 (Fed. Cir. 1997).” In this case, the claims are drawn to an isolated polypeptide “defined by” SEQ ID NO:5 or 6 (claims 1 and 7-8) or an isolated polypeptide consisting of SEQ ID NO:3, 5, or 6, except for a single mutation at position 73 or 81 (claims 9 and 21), or an isolated polypeptide consisting of SEQ ID NO:5, except for a substitution of amino acids 255-258 with SEQ ID NO:7, 8, 9, 10, 11, 12, 13, or 14 (claim 22). According to the specification at pp. 21-24, the invention encompasses these proteins in a crystalline form. As such, the examiner has interpreted claims 1, 7-9, and 21-22 as encompassing the recited proteins in a crystalline form, particularly as the claims do not exclude such forms and would appear to be encompassed by the claims in view of the disclosure of the specification.

In determining compliance with the written description requirement, “the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed. See, e.g., *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555,

Art Unit: 1656

1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991)." In this case, while the specification discloses a non-crystalline form of the recited polypeptide, the specification fails to describe even a single *crystalline* form of the recited polypeptides, fails to disclose any relevant identifying characteristics of such crystals, and fails to disclose a method for making such crystals. While applicant may argue that a crystal of the recited proteins can be made according to the disclosed method and/or would have structural characteristics, e.g., space group and unit cell dimensions, of the crystal of SEQ ID NO:17, the prior art acknowledges that crystallization conditions and the structural characteristics of a protein crystal cannot be predicted *a priori*. See, e.g., Kierzek et al. (*Biophys Chem* 91:1-20; cited in the Office action mailed on 3/7/06), which teaches that "each protein crystallizes under a unique set of conditions that cannot be predicted from easily measurable physico-chemical properties" and that "crystallization conditions must be empirically established for each protein to be crystallized" (underline added for emphasis, p. 2, left column, top). See also the teachings of McPherson et al. (*Eur. J. Biochem.* 189:1-23, 1990; cited in the Office action mailed on 6/14/05), which states (p. 13, column 2), "Table 2 lists physical, chemical and biological variables that may influence to a greater or less extent the crystallization of proteins. The difficulty in properly arriving at a just assignment of importance for each factor is substantial for several reasons. Every protein is different in its properties and, surprisingly perhaps, this applies even to proteins that differ by no more than one or just a few amino acids." Table 2 is a list of 25 different variables that can or do affect protein crystallization. As McPherson points out trying to identify those variables that are most important for each

Art Unit: 1656

protein is extremely difficult and changing a protein by even a single amino acid can result in significant influences upon the change in which variables are important for successful crystallization. McPherson also goes on to teach, "[b]ecause each protein is unique, there are few means available to predict in advance the specific values of a variable, or sets of conditions that might be most profitably explored. Finally, the various parameters under one's control are not independent of one another and their interrelations may be complex and difficult to discern. It is therefore, not easy to elaborate rational guidelines relating to physical factors or ingredients in the mother liquor that can increase the probability of success in crystallizing a particular protein. The specific component and condition must be carefully deduced and refined for each individual."

As such, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicant was in possession of the claimed invention.

[7] Claims 1, 7-9, and 21-22 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a non-crystalline polypeptide as encompassed by the claims, does not reasonably provide enablement for crystalline forms of the recited polypeptides. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

"The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue." *In re Angstadt*, 537 F.2d 498, 504, 190 USPQ 214, 219 (CCPA 1976). Factors to be considered in determining whether undue experimentation is required are summarized in *In re Wands* (858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)) as follows: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. See MPEP § 2164.01(a). The Factors most relevant to the instant rejection are addressed in detail below.

*The breadth of the claims:* According to MPEP 2164.04, "[b]efore any analysis of enablement can occur, it is necessary for the examiner to construe the claims...and explicitly set forth the scope of the claim when writing an Office action." MPEP 2164.08 states, "[a]ll questions of enablement are evaluated against the claimed subject matter. The focus of the examination inquiry is whether everything within the scope of the claim is enabled. Accordingly, the first analytical step requires that the examiner determine exactly what subject matter is encompassed by the claims" (citation omitted) and "[w]hen analyzing the enabled scope of a claim, the teachings of the specification must not be ignored because claims are to be given their broadest reasonable interpretation that is consistent with the specification." As noted above, according to the specification at pp. 21-24, the claims encompass proteins in a crystalline form. As such, the examiner

has interpreted claims 1, 7-9, and 21-22 as encompassing the recited proteins in a crystalline form, particularly as the claims do not exclude such forms and would appear to be encompassed by the claims in view of the disclosure of the specification.

The state of the prior art; The level of one of ordinary skill; and The level of predictability in the art: The state of the art at the time of the invention acknowledges a high level of unpredictability for making a protein crystal or for making a protein variant with an expectation that it maintains the desired activity/utility. Regarding the claimed crystal, the reference of Branden et al. ("Introduction to Protein Structure Second Edition", Garland Publishing Inc., New York, 1999; cited in the Office action mailed on 3/7/06) teaches that "[c]rystallization is usually quite difficult to achieve" (p. 375) and that "[w]ell-ordered crystals...are difficult to grow because globular protein molecules are large, spherical, or ellipsoidal objects with irregular surfaces, and it is impossible to pack them into a crystal without forming large holes or channels between the individual molecules" (p. 374). Also, Drenth ("Principles of X-ray Crystallography," Springer, New York, 1995; cited in the Office action mailed on 3/7/06) teaches that "[t]he science of protein crystallization is an underdeveloped area" and "[p]rotein crystallization is mainly a trial-and-error procedure" (p. 1). One cannot predict *a priori* those conditions that will lead to the successful crystallization of a diffraction-quality crystal nor can one predict the space group symmetry or unit cell dimensions of the resulting crystal. See Kierzek et al. (*Biophys Chem* 91:1-20; cited in the Office action mailed on 3/7/06), which teaches that "each protein crystallizes under a unique set of conditions that cannot be predicted from easily measurable physico-chemical properties" and that "crystallization

Art Unit: 1656

conditions must be empirically established for each protein to be crystallized" (underline added for emphasis, p. 2, left column, top). See also the teachings of McPherson et al. (*Eur. J. Biochem.* 189:1-23, 1990; cited in the Office action mailed on 6/14/05), which states (p. 13, column 2), "Table 2 lists physical, chemical and biological variables that may influence to a greater or less extent the crystallization of proteins. The difficulty in properly arriving at a just assignment of importance for each factor is substantial for several reasons. Every protein is different in its properties and, surprisingly perhaps, this applies even to proteins that differ by no more than one or just a few amino acids."

Table 2 is a list of 25 different variables that can or do affect protein crystallization. As McPherson points out trying to identify those variables that are most important for each protein is extremely difficult and changing a protein by even a single amino acid can result in significant influences upon the change in which variables are important for successful crystallization. McPherson also goes on to teach, "[b]ecause each protein is unique, there are few means available to predict in advance the specific values of a variable, or sets of conditions that might be most profitably explored. Finally, the various parameters under one's control are not independent of one another and their interrelations may be complex and difficult to discern. It is therefore, not easy to elaborate rational guidelines relating to physical factors or ingredients in the mother liquor that can increase the probability of success in crystallizing a particular protein. The specific component and condition must be carefully deduced and refined for each individual." Thus, in view of these teachings, a skilled artisan would recognize there is a high level of unpredictability in making a protein crystal.

The amount of direction provided by the inventor; The existence of working examples: In this case, the specification fails to disclose even a single working example of a crystalline form of a polypeptide of the claims. While it is acknowledged that the specification need not disclose a working example to satisfy the enablement requirement (see MPEP 2164.02), it is noted that “[l]ack of a working example, however, is a factor to be considered, especially in a case involving an unpredictable and undeveloped art.” Because the art of protein crystallography is clearly unpredictable as noted above, the lack of a working example has been considered in the enablement analysis.

The quantity of experimentation needed to make or use the invention based on the content of the disclosure: Methods of protein crystallography were known at the time of the invention. However, as methods for crystallizing a protein could not be determined *a priori* and must be determined by a trial and error process, *de novo* crystallization of a protein – if one could even achieve crystallization – was not routine at the time of the invention.

In view of the overly broad scope of the claims, the lack of guidance and working examples provided in the specification, the high level of unpredictability as evidenced by the prior art, and the amount of experimentation required to make and use all crystals and polypeptides as broadly encompassed by the claims, undue experimentation would be necessary for a skilled artisan to make and use the entire scope of the claimed invention. Thus, applicant has not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated

Art Unit: 1656

with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

### ***Claim Rejections - 35 USC § 103***

[8] The rejection of claim 1 under 35 U.S.C. 103(a) as being unpatentable over Borowski et al. (*Eur. J. Biochem.* 266:715-723, 1999) in view of Cho et al. (*J. Biol. Chem.* 273:15045-15052; cited as reference AG in the IDS filed on 14 December 2005) and Kim et al. (US Patent 6,183,121) is withdrawn in view of the amendment to the claims to delete SEQ ID NO:3 and 17 from claim 1.

### ***Conclusion***

[9] Status of the claims:

Claims 1, 7-9, 11, and 21-22 are pending.

Claims 1, 7-9, and 21-22 are rejected.

Claim 11 appears to be in condition for allowance.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Steadman whose telephone number is 571-272-0942. The examiner can normally be reached on Mon to Fri, 7:30 am to 4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr Bragdon can be reached on 571-272-0931. The fax phone

Art Unit: 1656

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



David J. Steadman, Ph.D.  
Primary Examiner  
Art Unit 1656